Related Experiment Video
Updated: Apr 27, 2026
Robot-Assisted Kidney Transplantation
Published on: July 19, 2021
[De novo urologic tumors in kidney transplant patients]
O Rodríguez Faba1, A Breda1, L Gausa1
1Unidad de Trasplante Renal, Servicio de Urología, Fundació Puigvert, Barcelona, España; Unidad de Urología Oncológica, Servicio de Urología, Fundació Puigvert, Barcelona, España.
Context:
The ability of a transplant recipient to accept a graft depends on the ability of immunosuppressive drugs to regulate the immune system. Such treatments have been associated with tumor promotion and progression.
Evidence Acquisition:
A systematic literature review was carried out. Electronic searches were performed in PubMed database. The searching criterion was "urological tumors in kidney transplant recipients". The most important issues regarding incidence, urological tumor-specific features, and relevant ones about the treatment are summarized.
Synthesis Of Evidence:
In renal transplant, 15% of all tumors are urological neoplasias; furthermore, they are the leading neoplastic cause of death. In transplant population the incidence rate of renal cell carcinoma (RCC), transitional cell bladder carcinoma (TCBC), testicular carcinoma (TC) and prostate cancer are increased 15, 3, 3 and 2 times respectively. Treatments used in transplant patients are similar to those employed in the general population:radical nephrectomy for the native kidney and conservative surgery for the graft are indicated for RCC. Radical prostatectomy is technically feasible for localized PC.Regarding to transitional cell carcinoma BCG or MMC is not contraindicated.
Conclusions:
The incidence rate of cancer has increased among transplant population. These tumors can be managed following the same criteria than in general population. Because in this population the prognosis is worse for the immunosuppression, closer monitoring is required.
Insights
Kidney transplant recipients face increased risks of urological tumors, including renal cell carcinoma, due to immunosuppression. Early detection and similar treatment strategies as the general population are crucial for better outcomes.
Area of Science:
- Uro-oncology
- Transplant medicine
- Immunosuppression research
Background:
- Immunosuppressive drugs are vital for transplant recipients but are linked to increased cancer risk.
- Urological tumors are a significant concern in the kidney transplant population.
Purpose of the Study:
- To summarize the incidence, features, and treatment of urological tumors in kidney transplant recipients.
- To provide an overview of current knowledge on urological neoplasias in this specific patient group.
Main Methods:
- A systematic literature review was conducted.
- Searches were performed in the PubMed database using the criterion "urological tumors in kidney transplant recipients".
Main Results:
- Urological cancers constitute 15% of all tumors in renal transplant patients and are the leading cause of cancer-related death.
- Incidence rates for renal cell carcinoma, transitional cell bladder carcinoma, testicular cancer, and prostate cancer are elevated 15, 3, 3, and 2 times, respectively.
- Treatment approaches for these cancers are generally similar to those in the general population.
Conclusions:
- Cancer incidence is higher in transplant recipients.
- Urological tumors in transplant patients can be managed similarly to the general population.
- Closer monitoring is essential due to poorer prognosis associated with immunosuppression.
More Related Videos
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management
01:28Kidney Transplant I: Introduction
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:25Urinary Tract Calculi VI: Surgical Management
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations